Source: International Congress 2018 – New trends in the management of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Wilkins (London, United Kingdom). New therapeutic targets in pulmonary arterial hypertension (PAH): moving from preclinical data to phase 2 studies. International Congress 2018 – New trends in the management of pulmonary hypertension

Member's Comments

No comment yet.

Related content which might interest you: New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension Source: Eur Respir Rev 2013; 22: 495-502 Year: 2013 Applying pharmacogenomics to pulmonary arterial hypertension (PAH): A target-based approach to therapy Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Clinical trial design and new therapies for pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018 Year: 2019 “New potential diagnostic biomarkers for pulmonary hypertension.” Source: Eur Respir J 2016; 48: 962 Year: 2016 New horizons in pulmonary arterial hypertension therapies Source: Eur Respir Rev 2013; 22: 503-514 Year: 2013 The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Macitentan in incident and prevalent pulmonary arterial hypertension (PAH): OPUS/OrPHeUS real-world data Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Novel therapeutic perspectives in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 193-194 Year: 2003 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 New potential diagnostic biomarkers for pulmonary hypertension Source: Eur Respir J 2015; 46: 1390-1396 Year: 2015 Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS) Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in who class II pulmonary arterial hypertension (PAH) patients: EARLY study results Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007